Chauhan Weighted Trajectory Analysis of combined efficacy and safety outcomes for risk-benefit analysis

Utkarsh Chauhan; Daylen Mackey; John R Mackey

Home/Archive/arXiv

arXiv · 2409.13946

Chauhan Weighted Trajectory Analysis of combined efficacy and safety outcomes for risk-benefit analysis

Utkarsh Chauhan·Daylen Mackey·John R Mackey

View original source ↗Read source document ↗Export metadata ↓

Abstract

Analyzing and effectively communicating the efficacy and toxicity of treatment is the basis of risk benefit analysis (RBA). More efficient and objective tools are needed. We apply Chauhan Weighted Trajectory Analysis (CWTA) to perform RBA with superior objectivity, power, and clarity. We used CWTA to perform 1000-fold simulations of RCTs using ordinal endpoints for both treatment efficacy and toxicity. RCTs were simulated with 1:1 allocation at defined sample sizes and hazard ratios. We studied the simplest case of 3 levels each of toxicity and efficacy and the general case of the advanced cancer trial, with efficacy graded by five RECIST 1.1 health statuses and toxicity by the six-point CTCAE scale (6 x 5 matrix). The latter model was applied to a real-world dose escalation phase I trial in advanced cancer. Simulations in both the 3 x 3 and the 6 x 5 advanced cancer matrix confirmed that drugs with both superior efficacy and toxicity profiles synergize for greater statistical power with CWTA-RBA. The CWTA-RBA 6 x 5 matrix reduced sample size requirements over CWTA efficacy-only analysis. Application to the dose finding phase I clinical trial provided objective, statistically significant validation for the selected dose. CWTA-RBA, by incorporating both drug efficacy and toxicity, provides a single test statistic and plot that analyzes and effectively communicates therapeutic risks and benefits. CWTA-RBA requires fewer patients than CWTA efficacy-only analysis when the experimental drug is both more effective and less toxic. CWTA-RBA facilitates the objective and efficient assessment of new therapies throughout the drug development pathway. Furthermore, several advantages over competing tests in communicating risk-benefit will assist regulatory review, clinical adoption, and understanding of therapeutic risks and benefits by clinicians and patients alike.

Explore related subjects

stat.ME

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Utkarsh Chauhan, Daylen Mackey, John R Mackey. 2024-09-20. Chauhan Weighted Trajectory Analysis of combined efficacy and safety outcomes for risk-benefit analysis. https://arxiv.org/abs/2409.13946

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Generalised Covariances and Correlations

The covariance of two random variables measures the average joint deviations from their respective means. We generalise this well-known measure by replacing the means with other statistical functionals such as quantiles, expectiles, or thresholds. Deviations from these functionals are defined via generalised errors, typically induced through identification or moment functions. As a normalised measure of dependence, a generalised correlation is constructed. Replacing the common Cauchy--Schwarz normalisation by a novel Fréchet--Hoeffding normalisation, we obtain attainability of the entire interval $[-1, 1]$ for any given marginal distributions. We uncover favourable properties of these new dependence measures and establish consistent estimators. The families of quantile and threshold correlations make it possible to measure local dependence and give rise to function-valued distributional correlations, exhibiting the entire dependence structure. Quantile correlations also lead to tail correlations, new measures of tail dependence, closely related to and refining classical coefficients of tail dependence. Finally, we construct summary covariances (correlations), a class of regional or global dependence measures, which arise as (normalised) weighted averages of distributional covariances. We retrieve covariance, Pearson and Spearman correlation as special cases. The usefulness of our new dependence measures is illustrated on demographic data from the Panel Study of Income Dynamics.

stat.ME↗

arXiv2026

Compressive Bayesian non-negative matrix factorization for mutational signatures analysis

Non-negative matrix factorization (NMF) is a popular tool for dimensionality reduction, especially for count matrices. However, inferring an appropriate number of factors is challenging. Existing approaches based on information criteria or nonparametric sparsity-inducing priors tend to be computationally burdensome or highly sensitive to prior choices. Moreover, theoretical properties of the posterior distribution of Poisson NMF parameters endowed with shrinkage priors remain under-explored. This paper introduces a novel Bayesian NMF method that automatically infers the number of factors while also incorporating information on the latent factors from previous studies. This is achieved using compressive hyperpriors, which are hierarchical priors that make the sample-specific weights of unneeded factors concentrate near zero in the posterior. We provide novel distribution theory for posterior inference to elucidate this shrinkage mechanism, both in finite samples and asymptotically. We apply our method to mutational signatures analysis in cancer genomics, in simulations and on real data from breast cancer. Compared to state-of-the-art alternatives, our method is more robust to mild overdispersion and improves detection and estimation of signatures aligned with prior information.

stat.ME↗

arXiv2026

On Relative Cumulative Residual Information Measure and Its Applications

We develop a relative cumulative residual information measure (RCRI) that aims to quantify the divergence between two survival functions. The dynamic relative cumulative residual information (DRCRI) measure is also introduced. We establish some characterization results under the assumption of the proportional hazards model. Additionally, we obtained the non-parametric estimators of RCRI and DRCRI measures based on the kernel density type estimator for the survival function. The effectiveness of the estimators are assessed through an extensive Monte Carlo simulation study. We consider data from the third Gaia data release (Gaia DR3) to demonstrate the use of the proposed measure. For this study, we have collected epoch photometry data for the objects Gaia DR3 4111834567779557376 and Gaia DR3 5090605830056251776. RCRI-based image analysis is conducted using Chest X-ray data from the publicly available dataset.

stat.ME↗